Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company's immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product's composition and manufacturing method. ABOUT ENLIV ...